Viron logo
  • Contact Us
  • Site Map
  • Home
  • About Us
  • Novel Platform
  • Product Candidates
  • Partnerships
  • Investors
  • Media Room
  • Careers

Quick Links

  • Management
  • Board of Directors
  • Novel Platform
  • Clinical Programs

SITEMAP

  • Home
  • About Us
    • BOARD OF DIRECTORS
    • MANAGEMENT
  • Novel Platform
    • SAFETY
    • EFFICACY
    • TECHNOLOGY PLATFORM
  • Product Candidates
    • PRODUCT PIPELINE
    • VT-111 (SERINE PROTEASE INHIBITOR)
    • VT-346 (TNF-α BINDING PROTEIN)
    • VT-384 (IL-18 BINDING PROTEIN)
    • VT-214 (CHEMOKINE BINDING PROTEIN)
    • VT-310 (IL-10 HOMOLOGUE)
    • VT-362 (CD-30 HOMOLOGUE)
    • DISCOVERY
  • Partnerships
  • Investors
    • INQUIRIES
    • OVERVIEW
  • Media Room
    • Viron Phase 2a Data Published in Leading Cardiovascular Journal
    • Viron awarded the Windhover 2011 "Top Biopharma Projects to Watch"
    • Viron Reports Positive Proof of Concept Results in Arthritis for its VT-346 anti-TNF Therapeutic
    • Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates
    • Viron Reports Positive Phase II Data in Acute Coronary Syndromes (ACS) Patients
    • Viron to Present Data from Phase II Trial at American Heart Association Conference
  • Careers
    • CAREER OPPORTUNITIES
    • PRIVACY POLICY
    • CONTACT US
Software Entwicklung NRW
© 2012 Viron Therapeutics, Inc. - All Rights Reserved
  • HOME
  • LEGAL
  • Terms of Use
  • Privacy
  • SITEMAP